Shaheenah Dawood, Consultant Medical Oncologist at Mediclinic Middle East, shared a post on LinkedIn:
“neoADAURA
Presented at ASCO, and now we see the ctDNA clearance data.
Addition of Osimertinib to neoadjuvant chemo increases MRD clearance compared to chemo alone.
Unfortunately, no arm of OSI alone here to see if chemo is actually required in the neoadjuvant setting!”
More from Shaheenah Dawood on OncoDaily.